|
|
|
News Releases>
Bausch & Lomb Technolas ® 217A Excimer Laser System
Receives FDA Approval for the Treatment of Hyperopia with Astigmatism
Feb 25, 2003 --
Bausch & Lomb announced Tuesday February 25, 2003 that its Bausch & Lomb Technolas ® 217A Excimer Laser System has been approved by the U.S. Food and Drug Administration (FDA) for the correction of hyperopia up to +4.00 diopters and the treatment of astigmatism up to +2.00 diopters when used as part of the LASIK surgical procedure.
The increased treatment range means that more patients may potentially benefit from LASIK surgery using the Bausch & Lomb Technolas ® 217A Excimer Laser System. Approximately 15 percent of people who require vision correction in the United States are farsighted.
The Bausch & Lomb Technolas ® 217A Excimer Laser System is the worldwide leader in laser placements and demonstrated unmatched clinical results when it received initial FDA approval for low/moderate myopia.
“This new indication is one more reason why the Bausch & Lomb Technolas ® 217A Excimer Laser System discriminating surgeon’s choice for providing patients exceptional vision correction,” said Robert J. Moore, Bausch & Lomb vice president, Marketing – The Americas Region. “With its expanded treatment range for myopia and its active eye tracking system, this laser has provided exceptional clinical outcomes for patients with myopia”.
“As medical director of UltraVision, I am personally thrilled with the approval of hyperopia and astigmatism for the Bausch & Lomb Technolas ® 217A Excimer Laser System. I am looking forward to adding this indication to my practice with the use of such laser, the only in San Antonio. However, the real winners here are my patients. They will now have the same superb technology that my myopes have become accustomed to,” said Tomy Starck, M.D. of San Antonio, a recognized leader in refractive surgery.
|
|
